MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October ...(n a complex PCI procedure broadcasted li...)

Date:11/10/2008

n a complex PCI procedure broadcasted live from Krakow, Poland to TCT '08 attendees. The procedure was performed by Dr. Dariusz Dudek and moderated by Dr. Martin Leon. The patient was suffering from an acute MI (heart attack) and initial angiography demonstrated a large thrombus obstructing the right coronary artery. MGuard(TM) was successfully delivered in an extremely complex procedure involving the use of new imaging techniques aimed to locate the best site to deploy the stent. When asked about the case and his experience with the MGuard(TM), Dr. Dudek stated: "We performed direct stenting on a patient with an acute myocardial infarction and a very large thrombotic lesion. We used an MGuardTM stent which covered the entire thrombus, preventing defragmentation and massive embolization. The final result was very good with a final TIMI 3 flow and a very good myocardial blush. I think that the MGuardTM stent system helped us to achieve very good results in a very difficult set up."

The MGuard(TM) breakfast meeting symposium "A New Approach to Treating Thrombus Containing Lesions (ACS, AMI and SVG)" was a great sensation. The meeting room was filled to its maximum capacity while additional attendees stood and listened in the halls outside the room. Dr. Martin Leon chaired the meeting and presented MGuard(TM) solutions for current stenting problems such as distal macro and micro embolization, axial displacement, persistent intra-luminal narrowing, and increased neointimal hyperplasia. Dr. Abizaid presented the outstanding interim results of the ongoing Brazil multi-center GUARD study and Dr. Artur Dziewierz from Dr. Dudek's clinic presented excellent preliminary study results from the ongoing MGuard(TM) STEMI MAGICAL (MGuard(TM) in SVG and Native Coronaries) trial in Krakow, Poland. Additional speakers and panel members at the meeting included Yaron Almagor MD, Chaim Lotan MD, and Carlo Di Mario MD. The panel discussions included the promise and future potential
'/>"/>

SOURCE InspireMD, Ltd. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
2. SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
5. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
6. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
7. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
8. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
9. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
10. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
11. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer